89Zr-TLX250

DRUG3 trials

Sponsors

Institut Cancerologie de l'Ouest, Telix Pharmaceuticals (Innovations) Pty Limited

Conditions

Advanced Renal Cell CarcinomaAdvanced Solid TumorBladder CancerSolid Tumor, AdultTriple Negative Breast Cancer

Early Phase 1

Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC

CompletedNCT04897763

Institut Cancerologie de l'OuestBladder Cancer

Start: 2021-12-15End: 2022-09-26Updated: 2026-01-07

Phase 1

Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors

RecruitingNCT05868174

Telix Pharmaceuticals (Innovations) Pty LimitedAdvanced Renal Cell Carcinoma, Advanced Solid Tumor, Solid Tumor, Adult

Start: 2023-05-23End: 2026-12-31Target: 36Updated: 2024-05-01

Phase 2

Imaging Performance Assessment of 89Zi-girentuximab (89Zr-TLX250) PET in Metastatic Triple Negative Breast Cancer

CompletedNCT04758780

Institut Cancerologie de l'OuestTriple Negative Breast Cancer

Start: 2021-09-21End: 2023-09-13Updated: 2026-07-20

Related Papers

Prospective pilot study with [<sup>89</sup>Zr]Zr-girentuximab PET/CT: CA-IX imaging in metastatic triple negative breast cancer (OPALESCENCE).

2025-11-01

Abstract PO2-06-13: Promising clinical performance of 89Zirconium-labelled Girentuximab PET-CT for imaging metastatic triple negative breast cancer patients (OPALESCENCE)

Cancer Research2024-05-02